PharmTech News

Articles

AstraZeneca has announced that the mass rollout of its COVID-19 vaccine has begun via the COVAX initiative. 

AstraZeneca Progresses Rollout of COVID-19 Vaccine to Low- and Middle-Income Countries

Oxular has raised US $37 million in a financing round led by specialist life sciences investor, Forbion.

Oxular Completes Financing Round Worth $37 million

Arcline Investment Management has acquired ChargePoint Technology, strengthening its global presence.

Arcline Investment Management Acquires ChargePoint Technology

Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.

WuXi AppTec Acquires OXGENE to Increase Cell and Gene Therapy Offerings

The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.

Roche and Cambridge Quantum Computing Use Algorithms for Early Alzheimer's Drug Research

The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.

SPT Labtech Strengthens Automation Services with BioMicroLab Acquisition

The new ultra-sensitive second-generation micro-chip technology is a key enabler in advanced single-cell proteomics workflow.

PharmaFluidics Offers Second-Gen µPAC Technology for Single Cell Proteomics

Through the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities.

Seven Bridges to Support Pfizer’s Data Management Solution for Single-Cell RNA Sequencing

Currently, the facility manufactures products for oral diabetes treatment and will be expanded to increase capacity for these products.

Novo Nordisk to Invest $80 million into the Expansion of its Denmark Production Site

Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.

Supplier News